We are live on ! Find out more
VIA

Vident Investment Advisory Portfolio holdings

AUM $2.9B
1-Year Est. Return 24.67%
This Fund
S&P 500
This Quarter Est. Return
+7.27%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
–
AUM
$1.85B
AUM Growth
+$639M
Cap. Flow
+$551M
Cap. Flow %
29.85%
Top 10 Hldgs %
16.26%
Holding
807
New
369
Increased
263
Reduced
92
Closed
81

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$17.6M
2
XLNX
Xilinx Inc
XLNX
+$12.8M
3
IPGP icon
IPG Photonics
IPGP
+$12.6M
4
RAVN
Raven Industries Inc
RAVN
+$12.4M
5
CDNS icon
Cadence Design Systems
CDNS
+$11.9M

Top Sells

Rank Stock Value
1
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$3.34M
2
HUN icon
Huntsman Corp
HUN
+$2.99M
3
STT icon
State Street
STT
+$2.9M
4
PFG icon
Principal Financial Group
PFG
+$2.84M
5
LPNT
LifePoint Health, Inc.
LPNT
+$2.76M

Sector Composition

Rank Sector Weight
1 Technology 22.97%
2 Industrials 14.16%
3 Healthcare 11.61%
4 Financials 7.62%
5 Consumer Discretionary 7.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
326
Incyte
INCY
$24B
$1.32M 0.07%
9,752
+1,184
+14% +$150K
PFE icon
327
Pfizer
PFE
$149B
$1.32M 0.07%
38,915
+24,556
+171% +$789K
PEP icon
328
PepsiCo
PEP
$189B
$1.31M 0.07%
+11,796
New +$1.36M
BBBY
329
DELISTED
Bed Bath & Beyond Inc
BBBY
$1.31M 0.07%
55,815
+5,348
+11% +$150K
TGT icon
330
Target
TGT
$66.8B
$1.31M 0.07%
+22,191
New +$1.24M
MCD icon
331
McDonald's
MCD
$196B
$1.3M 0.07%
8,286
+6,302
+318% +$988K
TCRT icon
332
Alaunos Therapeutics
TCRT
$4.86M
$1.3M 0.07%
1,408
+43
+3% +$38.2K
XNCR icon
333
Xencor
XNCR
$1.49B
$1.29M 0.07%
56,137
+1,701
+3% +$37.8K
TWX
334
DELISTED
Time Warner Inc
TWX
$1.28M 0.07%
+12,463
New +$1.26M
BLCM
335
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.27M 0.07%
10,965
+333
+3% +$35K
LLY icon
336
Eli Lilly
LLY
$1.06T
$1.26M 0.07%
14,712
+10,989
+295% +$901K
MSFT icon
337
Microsoft
MSFT
$3.71T
$1.25M 0.07%
16,848
+3,390
+25% +$248K
SNDX icon
338
Syndax Pharmaceuticals
SNDX
$1.76B
$1.25M 0.07%
106,794
+3,236
+3% +$39.7K
AGN
339
DELISTED
Allergan plc
AGN
$1.24M 0.07%
6,052
+4,745
+363% +$1.1M
NVS icon
340
Novartis
NVS
$293B
$1.24M 0.07%
16,079
+486
+3% +$36.7K
EW icon
341
Edwards Lifesciences
EW
$51.5B
$1.23M 0.07%
+33,711
New +$1.29M
ABBV icon
342
AbbVie
ABBV
$431B
$1.22M 0.07%
+13,694
New +$1.04M
BABA icon
343
Alibaba
BABA
$304B
$1.21M 0.07%
+7,024
New +$1.14M
MGNX icon
344
MacroGenics
MGNX
$255M
$1.21M 0.07%
65,269
+1,977
+3% +$34.2K
NLY icon
345
Annaly Capital Management
NLY
$17.1B
$1.2M 0.06%
24,510
+21,807
+807% +$1.07M
KDNY
346
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.17M 0.06%
21,963
+552
+3% +$32.8K
WYNN icon
347
Wynn Resorts
WYNN
$10.5B
$1.17M 0.06%
+7,836
New +$1.07M
AZN icon
348
AstraZeneca
AZN
$250B
$1.15M 0.06%
16,992
+515
+3% +$32.5K
GCI
349
DELISTED
Gannett Co., Inc
GCI
$1.15M 0.06%
127,867
-7,375
-5% -$63.3K
ALXN
350
DELISTED
Alexion Pharmaceuticals
ALXN
$1.13M 0.06%
+8,065
New +$1.1M
12 13
14
15 16

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
WI
Winder Investment Singapore $4.4B AUM 8.87% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return

Vident Investment Advisory's Q3 2017 Portfolio in Review

As of Q3 2017, Vident Investment Advisory held 807 positions worth $1.85B, up 53% from $1.21B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Vident Investment Advisory deployed $551M of net new capital in Q3 2017, opening 369 new positions and adding to 263 existing holdings. Its largest new stake was Xilinx Inc: 195,171 shares worth $13.8M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Industrials and Healthcare.

On the sell side, the largest reduction was Berkshire Hathaway Class B, an estimated $3.34M trimmed.

  • Vident Investment Advisory's largest Q3 2017 buy was Xilinx Inc: 195,171 shares worth $13.8M.
  • Vident Investment Advisory added most to State Street SPDR S&P 500 ETF Trust in Q3 2017, an estimated $17.6M increase.
  • Vident Investment Advisory's biggest Q3 2017 reduction was Berkshire Hathaway Class B, cutting an estimated $3.34M.
  • Vident Investment Advisory fully exited Huntsman Corp in Q3 2017, selling an estimated $2.99M.
  • Vident Investment Advisory's ten largest holdings make up 16% of its $1.85B portfolio in Q3 2017.
  • Vident Investment Advisory opened 369 new positions and closed 81 in Q3 2017.
  • Vident Investment Advisory's portfolio value rose 53% quarter-over-quarter to $1.85B.

Based on Vident Investment Advisory's 13F filing for Q3 2017, filed 14 Nov 2017.